See more : Aeterna Zentaris Inc. (AEZS.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Axcella Health Inc. (AXLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axcella Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- COCOLIVE INC (137A.T) Income Statement Analysis – Financial Results
- Amprius Technologies, Inc. (AMPX) Income Statement Analysis – Financial Results
- Dialight plc (DIALF) Income Statement Analysis – Financial Results
- Hydrotek Public Company Limited (HYDRO.BK) Income Statement Analysis – Financial Results
- PGE Polska Grupa Energetyczna S.A. (PGE.WA) Income Statement Analysis – Financial Results
Axcella Health Inc. (AXLA)
About Axcella Health Inc.
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.98M | 43.14M | 37.04M | 41.66M | 25.49M | 22.92M |
| General & Administrative | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Other Expenses | 0.00 | -4.00K | 10.00K | 34.00K | 0.00 | 0.00 |
| Operating Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Cost & Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Interest Income | 504.00K | 139.00K | 306.00K | 1.81M | 0.00 | 0.00 |
| Interest Expense | 3.02M | 2.92M | 3.01M | 3.40M | 0.00 | 0.00 |
| Depreciation & Amortization | 412.00K | 288.00K | 419.00K | 51.00K | 1.07M | 1.39M |
| EBITDA | -67.01M | -61.85M | -53.84M | -57.39M | -32.81M | -27.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.80M | -61.85M | -53.84M | -57.44M | -33.90M | -28.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.39M | -2.78M | -2.69M | -1.60M | -2.17M | -2.02M |
| Income Before Tax | -81.19M | -64.63M | -56.53M | -59.04M | -36.07M | -30.94M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.49M | 2.28M | 936.00K | -2.17M | 2.02M |
| Net Income | -81.19M | -67.12M | -58.81M | -59.97M | -36.07M | -30.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| EPS Diluted | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| Weighted Avg Shares Out | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
| Weighted Avg Shares Out (Dil) | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
Why Is Axcella Health (AXLA) Stock Up 68% Today?
Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that would act as a...
Axcella Reports Second Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June...
Axcella Reports First Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a...
Axcella Reports First Quarter Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the first quarter ended March 31, 2023 and provided a...
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two oral presentations of results from the Phase 2a clinical trial of AXA1125 in...
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced two oral presentations of results from the Phase 2a clinical trial of AXA1125 in...
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022...
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022...
Why Is Axcella Health (AXLA) Stock Up 35% Today?
Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid Fatigue treatment currently in development.
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the...
Source: https://incomestatements.info
Category: Stock Reports